Table 1.

Demographics and Clinical Data (n=28)

		Number (% of Total)	Median ± IQR (range)
Age (years)			13 ± 8.5 (2–21)
Female/Male		23 (82%)/5 (18%)
Race: Caucasian/African-American/Asian		26 (93%)/1 (4%)/1 (4%)
JIA subtype
Enthesitis-related		2 (7%)
Oligoarthritis extended		1 (4%)
Oligoarthritis persistent		8 (29%)
Polyarthritis RF* negative		11 (39%)
Polyarthritis RF positive		2 (7%)
Psoriatic		2 (7%)
Presence of uveitis		5 (18%)
Medications
NSAIDs∫		22 (79%)
Methotrexate		10 (36%)
Any biologic		8 (29%)
Prednisone		1 (4%)
Number of active joints			6 ± 8 (1–16)
Duration JIA (months)			24 ± 41 (4–84)
Duration of TMJ disease (months)			3 ± 12.5 (1–24)

^*RF: Rheumatoid factor,

^∫NSAID: Non-steroidal anti-inflammatory drugs